摘要
目的探讨非小细胞肺癌组织中表皮生长因子受体-2(HER-2)和肺耐药蛋白(LRP)的表达及与临床病理特征的关系。方法应用免疫组织化学(IHC)EnVision二步法,检测70例非小细胞肺癌组织和35例相应癌旁正常肺组织中HER-2和LRP的表达情况,并结合其临床病理特征进行分析。结果在非小细胞肺癌组织中,HER-2和LRP的阳性表达率分别为31.4%、72.9%,均分别高于癌旁正常肺组织的表达(P<0.05)。HER-2在腺癌中的阳性表达率为46.0%,在鳞癌中为15.2%,两者差异有统计学意义(P<0.05)。HER-2的表达与淋巴结转移、病理分级、临床分期间无明显差异(P>0.05);LRP在腺癌中的阳性表达率为78.4%,在鳞癌中为66.7%(P>0.05)。LRP的表达与淋巴结转移、病理分级及临床分期间的差异有统计学意义(P<0.05)。结论 HER-2、LRP在非小细胞肺癌组织中有不同程度的表达,检测两者有助于该癌化疗药物的选择及预后的判断。
Objective To investigate associations between the expression of lung resistance protein（LRP） and human epidermal growth factor receptor 2（HER-2） and the clinico-pathological features of non-small cell lung cancer. Methods The two-step EnVision immunohistochemical method was used to measure the expression of HER-2 and LRP in 70 cases of non-small cell lung cancer tissues, and 35 corresponding adjacent normal lung tissues. Results Expression rates of HER-2 and LRP were significantly higher in cancer tissue （31.4% and 72.9%,respectively） than in adjacent normal lung tissue （P〈0.05）. The expression rate of HER-2 was significantly higher in adenocarcinoma （46.0%） than in squamous cell carcinoma （15.2%; P〈0.05）. However,HER-2 expression did not correiate with lymph node metastasis ,pathologic classification or clinical staging （P〉0.05）.The expression rate of LRP was similar in adenocarcinoma and squamous cell carcinoma （78.4 vs 66.7%,P〉0.05）,and LRP expression correlated with lymph node metastasis, pathologic classification, and clinical staging（P〈0.05 ）. Conclusions HER-2 and LRP proteins are expressed to different degrees in non- small cell lung cancer.Assaying for both may be valuable for designing chemotherapy and predicting prognosis in non-small ceil lung cancer.
出处
《中国癌症防治杂志》
CAS
2013年第4期315-319,共5页
CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT
